MapLight Therapeutics, Inc. MPLT Proceeds From Initial Public Offering Of Common Stock And Private Placement Net Of Underwriting Fees
Proceeds From Initial Public Offering Of Common Stock And Private Placement Net Of Underwriting Fees at other companies
Other financials
Where this comes from
Reported directly by MapLight Therapeutics, Inc. in its filing.
Tagged under the XBRL concept mplt:ProceedsFromInitialPublicOfferingOfCommonStockAndPrivatePlacementNetOfUnderwritingFees.
The official record: MapLight Therapeutics, Inc. ’s 10-K, filed March 26, 2026, on SEC EDGAR. View the filing →
Ask your AI about MapLight Therapeutics, Inc. 's proceeds from initial public offering of common stock and private placement net of underwriting fees.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is MapLight Therapeutics, Inc. 's proceeds from initial public offering of common stock and private placement net of underwriting fees?
- MapLight Therapeutics, Inc. (MPLT) reported proceeds from initial public offering of common stock and private placement net of underwriting fees of $68.93M in Q4 2025.
- What does proceeds from initial public offering of common stock and private placement net of underwriting fees mean?
- This represents the net cash proceeds generated from the company's public market debut and subsequent private placements, after deducting underwriting fees and related issuance costs. It serves as a primary indicator of the capital raised to fund long-term clinical development and operational scaling. This metric is a key measure of the company's ability to access public equity markets to support its growth trajectory.